Medpace

1) Strong Business Environment and Awards Growth - The business environment remains robust, with high-quality RFP activity and strong initial award notifications. - Net new business awards reached an all-time high of $873 million in Q3 2026, reflecting a 10.6% increase YoY. - The last 12-month closing awards grew by 23.9%, indicating a healthy demand for Medpace's services. - The company anticipates providing guidance for 2027 in February, with no significant disconnect from analyst consensus estimates.

2) Financial Performance Highlights - Q3 2026 revenue was $716 million, up 8.5% YoY; year-to-date revenue reached $2.13 billion, a 16.9% increase. - EBITDA for Q3 was $172.1 million, a 16% increase from $148.4 million in Q3 2025, with an EBITDA margin of 24% compared to 22.5% YoY. - Net income for Q3 was $137.5 million, up 23.7% YoY, with net income per diluted share at $4.84, compared to $3.86 in Q3 2025. - Year-to-date net income totaled $382.7 million, a 21.1% increase from the previous year.

3) Operational Insights and Challenges - Backlog as of September 30, 2026, was approximately $3.2 billion, a 5.6% increase YoY, with $1.99 billion expected to convert to revenue in the next 12 months. - Cancellations were noted to be higher than desired but within expected ranges, primarily due to product failures rather than funding issues. - The company is experiencing a shift in therapeutic focus back towards traditional oncology, with a decrease in metabolic demand.

4) Guidance and Future Outlook - Full-year 2026 revenue is projected to be between $2.835 billion and $2.855 billion, indicating growth of 12% to 12.8% over 2025. - EBITDA for 2026 is expected to range from $638 million to $652 million, reflecting growth of 14.4% to 16.9%. - The effective tax rate for 2026 is projected to be between 19% and 19.5%, with no additional share repurchases assumed in the guidance.

5) Investor Considerations - The call did not provide specific details on the competitive landscape or pricing strategies, which may be relevant for investors assessing market positioning. - Further clarity on 2027 guidance will be provided in February, which is critical for understanding future growth trajectories.

Bottom line: Medpace is demonstrating strong financial growth and operational resilience, with a solid backlog and increasing awards, positioning itself well for future performance despite some challenges with cancellations. Investors should watch for the upcoming guidance in February to better assess growth expectations for 2027.